P. Cassier et al.ESMO 2021Download the poster herePoster Presentation
Catégorie : TG6002
Transgene présente des données de Phase I confirmant le potentiel du virus oncolytique TG6002
Transgene présente des données de Phase I confirmant le potentiel du virus oncolytique TG6002
3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation
Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation
Transgene présente les premières données de Phase I de TG6002, soulignant le potentiel de ses virus oncolytiques en administration intraveineuse
20210409 – TG6002 AACR FR
Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication
High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al. Molecular Therapy Oncolytics, September 2020 – Read the article and view videos Publication
Premières données positives dans un essai de Phase 1 du virus oncolytique de Transgene TG6002
20200908 Transgene TG6002 Phase 1 FR
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al. Molecular Therapy Oncolytics, September 2020 – Read the article Publication
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al. BMC Vet Res., August 25 2020 – Read the article Publication
